Targeting the cancer lesion, not the whole prostate

被引:9
作者
Bedi, Nishant [1 ,2 ]
Reddy, Deepika [1 ,2 ]
Ahmed, Hashim U. [1 ,2 ]
机构
[1] Imperial Coll Healthcare NHS Trust, Charing Cross Hosp, Imperial Urol, London, England
[2] Imperial Coll London, Dept Surg & Canc, Div Surg, Imperial Prostate, London, England
基金
英国惠康基金;
关键词
Prostate cancer; focal therapy; high-intensity focused ultrasound (HIFU); cryotherapy; index lesion; irreversible electroporation (IRE); vascular-targeted photodynamic therapy (VTP); focal brachytherapy; laser interstitial therapy (LITT); focal radiofrequency ablation (focal RFA); photodynamic therapy (PDT); INTENSITY FOCUSED ULTRASOUND; PROSPECTIVE MULTICENTRIC HEMIABLATION; FOCAL THERAPY; IRREVERSIBLE ELECTROPORATION; RADICAL PROSTATECTOMY; FUNCTIONAL OUTCOMES; INDEX LESION; FOLLOW-UP; BRACHYTHERAPY; CRYOTHERAPY;
D O I
10.21037/tau.2019.09.12
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Modern cancer treatment aims to conserve as much healthy tissue as possible. This has been challenging in the treatment of prostate cancer due to the difficulty in imaging the gland and concerns over leaving multifocal cancer untreated. With improvements in imaging and understanding of multifocal prostate cancer evidence now shows accurate treatment of just the primary focus of cancer or the index lesion can control progression or recurrence of the disease. Many different energy sources are now available to target the cancer lesion within the prostate with less significant side-effects on urinary and sexual function compared to radical treatment. Evidence shows that men value these functions highly and would even trade years of life in exchange for preserved retention of continence or erectile function. Focal treatment of prostate cancer aims to provide both cancer control and preservation of sexual and urinary functions so that men do not have to make a choice between the two. This is a treatment option that men clearly want and deserve.
引用
收藏
页码:1518 / 1525
页数:8
相关论文
共 56 条
  • [31] Lepor H, 2014, ONCOLOGY-NY, V28, P16
  • [32] Image Guided Photothermal Focal Therapy for Localized Prostate Cancer: Phase I Trial
    Lindner, U.
    Weersink, R. A.
    Haider, M. A.
    Gertner, M. R.
    Davidson, S. R. H.
    Atri, M.
    Wilson, B. C.
    Fenster, A.
    Trachtenberg, J.
    [J]. JOURNAL OF UROLOGY, 2009, 182 (04) : 1371 - 1377
  • [33] Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
    Liu, Wennuan
    Laitinen, Sari
    Khan, Sofia
    Vihinen, Mauno
    Kowalski, Jeanne
    Yu, Guoqiang
    Chen, Li
    Ewing, Charles M.
    Eisenberger, Mario A.
    Carducci, Michael A.
    Nelson, William G.
    Yegnasubramanian, Srinivasan
    Luo, Jun
    Wang, Yue
    Xu, Jianfeng
    Isaacs, William B.
    Visakorpi, Tapio
    Bova, Steven
    [J]. NATURE MEDICINE, 2009, 15 (05) : 559 - 565
  • [34] Mazzucchelli R, 2009, ANTICANCER RES, V29, P5155
  • [35] Does true Gleason pattern 3 merit its cancer descriptor?
    Miah, Saiful
    Ahmed, Hashim U.
    Freeman, Alex
    Emberton, Mark
    [J]. NATURE REVIEWS UROLOGY, 2016, 13 (09) : 541 - 548
  • [36] Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patient's Pathology and Clinical Reports
    Montironi, Rodolfo
    Cheng, Liang
    Lopez-Beltran, Antonio
    Scarpelli, Marina
    Mazzucchelli, Roberta
    Mikuz, Gregor
    Kirkali, Ziya
    Montorsi, Francesco
    [J]. EUROPEAN UROLOGY, 2010, 58 (03) : 369 - 373
  • [37] Updated Results of Magnetic Resonance Imaging Guided Partial Prostate Brachytherapy for Favorable Risk Prostate Cancer: Implications for Focal Therapy
    Nguyen, Paul L.
    Chen, Ming-Hui
    Zhang, Yuanye
    Tempany, Clare M.
    Cormack, Robert A.
    Beard, Clair J.
    Hurwitz, Mark D.
    Suh, W. Warren
    D'Amico, Anthony V.
    [J]. JOURNAL OF UROLOGY, 2012, 188 (04) : 1151 - 1156
  • [38] NICE, 2018, SINGL TECHN APPR PAD
  • [39] Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials)
    Noweski, A.
    Roosen, A.
    Lebdai, S.
    Barret, E.
    Emberton, M.
    Benzaghou, F.
    Apfelbeck, M.
    Gaillac, B.
    Gratzke, C.
    Stief, C.
    Azzouzi, A. R.
    [J]. EUROPEAN UROLOGY FOCUS, 2019, 5 (06): : 1022 - 1028
  • [40] Orczyk C, 2018, EUR UROL SUPPL, V17, pe784